VIPoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{VIPoma}}
{{VIPoma}}
{{CMG}}{{AE}}{{PSD}}{{MSI}}
{{CMG}}{{AE}}{{MSI}}{{PSD}}
==Overview==
==Overview==
VIPoma must be differentiated from ganglioneuroblastoma, [[ganglioneuroma]], factitious [[diarrhea]], bilt salt enteropathy, rectal vilous adenomas, and [[laxative abuse]].<ref name="pmid15455292">{{cite journal| author=Reindl T, Degenhardt P, Luck W, Riebel T, Sarioglu N, Henze G et al.| title=[The VIP-secreting tumor as a differential diagnosis of protracted diarrhea in pediatrics]. | journal=Klin Padiatr | year= 2004 | volume= 216 | issue= 5 | pages= 264-9 | pmid=15455292 | doi=10.1055/s-2004-44901 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15455292  }} </ref><ref name="pmid21509215">{{cite journal| author=Elshafie O, Grant C, Al-Hamdani A, Jain R, Woodhouse N| title=VIPoma Crisis: Immediate and life saving reduction of massive stool volumes on starting treatment with octreotide. | journal=Sultan Qaboos Univ Med J | year= 2011 | volume= 11 | issue= 1 | pages= 104-7 | pmid=21509215 | doi= | pmc=PMC3074686 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21509215  }} </ref>
VIPoma must be differentiated from ganglioneuroblastoma, [[ganglioneuroma]], factitious [[diarrhea]], bilt salt enteropathy, rectal vilous adenomas, and [[laxative abuse]].<ref name="pmid15455292">{{cite journal| author=Reindl T, Degenhardt P, Luck W, Riebel T, Sarioglu N, Henze G et al.| title=[The VIP-secreting tumor as a differential diagnosis of protracted diarrhea in pediatrics]. | journal=Klin Padiatr | year= 2004 | volume= 216 | issue= 5 | pages= 264-9 | pmid=15455292 | doi=10.1055/s-2004-44901 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15455292  }} </ref><ref name="pmid21509215">{{cite journal| author=Elshafie O, Grant C, Al-Hamdani A, Jain R, Woodhouse N| title=VIPoma Crisis: Immediate and life saving reduction of massive stool volumes on starting treatment with octreotide. | journal=Sultan Qaboos Univ Med J | year= 2011 | volume= 11 | issue= 1 | pages= 104-7 | pmid=21509215 | doi= | pmc=PMC3074686 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21509215  }} </ref>

Revision as of 03:30, 27 December 2017

VIPoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating VIPoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

VIPoma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of VIPoma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on VIPoma differential diagnosis

CDC on VIPoma differential diagnosis

VIPoma differential diagnosis in the news

Blogs on VIPoma differential diagnosis

Directions to Hospitals Treating VIPoma

Risk calculators and risk factors for VIPoma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3]

Overview

VIPoma must be differentiated from ganglioneuroblastoma, ganglioneuroma, factitious diarrhea, bilt salt enteropathy, rectal vilous adenomas, and laxative abuse.[1][2]

Differential Diagnosis

VIPoma must be differentiated from:[1]

The table below summarizes the findings that differentiate watery causes of chronic diarrhea[3][4][5][6]

Cause Osmotic gap History Physical exam Gold standard Treatment
< 50 mOsm per kg > 50 mOsm per kg*
Watery Secretory Crohns + -
Hyperthyroidism + -
VIPoma + -
  • Elevated VIP levels
  • Followed by imaging
Osmotic Lactose intolerance - +
Celiac disease - +
Functional Irritable bowel syndrome - -

Abdominal pain or discomfort recurring at least 3 days per month in the past 3 months and associated with 2 or more of the following:

  • Onset associated with change in frequency of stool
  • Onset associated with change in appearance of stool

History of straining is also common

Template:WikiDoc Sources

VIPoma must be differentiated from diseases that cause abdominal pain and chronic diarrhea. The table below summarizes the findings that differentiate watery causes of chronic diarrhea:[7][3][4][5][6]

Cause Osmotic gap History Physical exam Gold standard for diagnosis
< 50 mOsm per kg > 50 mOsm per kg*
Zollinger-Ellison syndrome + - Gastrin levels
Crohn's disease + -
Hyperthyroidism + -
VIPoma + -
  • Elevated VIP levels
  • Followed by imaging
Lactose intolerance - +
Celiac disease - +
Irritable bowel syndrome - -

Abdominal pain or discomfort recurring at least 3 days per month in the past 3 months and associated with 2 or more of the following:

  • Onset associated with change in frequency of stool
  • Onset associated with change in appearance of stool

History of straining is also common.


References

  1. 1.0 1.1 Reindl T, Degenhardt P, Luck W, Riebel T, Sarioglu N, Henze G; et al. (2004). "[The VIP-secreting tumor as a differential diagnosis of protracted diarrhea in pediatrics]". Klin Padiatr. 216 (5): 264–9. doi:10.1055/s-2004-44901. PMID 15455292.
  2. Elshafie O, Grant C, Al-Hamdani A, Jain R, Woodhouse N (2011). "VIPoma Crisis: Immediate and life saving reduction of massive stool volumes on starting treatment with octreotide". Sultan Qaboos Univ Med J. 11 (1): 104–7. PMC 3074686. PMID 21509215.
  3. 3.0 3.1 Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR; et al. (2005). "Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology". Can J Gastroenterol. 19 Suppl A: 5A–36A. PMID 16151544.
  4. 4.0 4.1 Sauter GH, Moussavian AC, Meyer G, Steitz HO, Parhofer KG, Jüngst D (2002). "Bowel habits and bile acid malabsorption in the months after cholecystectomy". Am J Gastroenterol. 97 (7): 1732–5. doi:10.1111/j.1572-0241.2002.05779.x. PMID 12135027.
  5. 5.0 5.1 Maiuri L, Raia V, Potter J, Swallow D, Ho MW, Fiocca R; et al. (1991). "Mosaic pattern of lactase expression by villous enterocytes in human adult-type hypolactasia". Gastroenterology. 100 (2): 359–69. PMID 1702075.
  6. 6.0 6.1 RUBIN CE, BRANDBORG LL, PHELPS PC, TAYLOR HC (1960). "Studies of celiac disease. I. The apparent identical and specific nature of the duodenal and proximal jejunal lesion in celiac disease and idiopathic sprue". Gastroenterology. 38: 28–49. PMID 14439871.
  7. SCOBIE BA, MCGILL DB, PRIESTLEY JT, ROVELSTAD RA (1964). "EXCLUDED GASTRIC ANTRUM SIMULATING THE ZOLLINGER-ELLISON SYNDROME". Gastroenterology. 47: 184–7. PMID 14201408.


Template:WikiDoc Sources